(Reuters) – AstraZeneca said on Friday a drug it is developing with Daiichi Sankyo’s to treat patients with a type of breast cancer met one of the main goals in a late-stage study.
(Reporting by Khushi Mandowara in Bengaluru; Editing by Nivedita Bhattacharjee)
